NCT04461249View on ClinicalTrials.gov

Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients

CompletedOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

February 28, 2020

Study Completion Date

April 1, 2020

Conditions
Primary Open Angle Glaucoma
Interventions
DRUG

Latanoprost 0.005% Ophthalmic Solution

Latanoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.

DRUG

Travoprost 0.004% ophthalmic solution

Travoprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.

DRUG

Tafluprost Ophthalmic 0.0015% Ophthalmic Solution

Tafluprost eye drops was given to newly diagnosed primary open-angle glaucoma patients once by night and intraocular pressure fluctuation was measured using Goldmann applanation tonometer.

Trial Locations (1)

Unknown

Kasr El-Aini hospital, Cairo

All Listed Sponsors
lead

Kasr El Aini Hospital

OTHER

NCT04461249 - Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients | Biotech Hunter | Biotech Hunter